Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

August 31, 2014

Conditions
Rectal Adenocarcinoma
Interventions
DRUG

Bevacizumab

Bevacizumab 5mg/m2 D1,D15,D29,D43;

DRUG

Oxaliplatin

Oxaliplatin 85mg/m2 D1,D57; Oxaliplatin 85mg/m2 biweekly \* 6 doses 3-4 weeks after radical resection

DRUG

5-FU

5-FU 2800mg/m2 civ 48 hours D1,D57; 5-FU 2800mg/m2 civ 48 hours biweekly\*6 doses 3-4 weeks after radical resection; 5-FU 200mg/m2/day civ D15-19,D22-26,D29-33,D36-40,D43-47;

RADIATION

Radiotherapy

2GY daily \*20次

Trial Locations (2)

510600

Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

510655

Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER

NCT01554059 - Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients | Biotech Hunter | Biotech Hunter